PPARy agonist for treatment of progressive supranuclear palsy
Methods of treatment of progressive supranuclear palsy or its symptoms, with PPARγ agonists, and in particular, the compound of formula (I) known as INT 131: Formula (I). Also provided are methods of treating a subject that include selecting a subject having an elevated level of neurofilament light chain protein in a sample obtained from the subject, as compared to a reference level of neurofilament light chain protein, and administering a pharmaceutical composition including a therapeutically effective amount of a compound of formula (I) to the selected subject.
1. A method of treating progressive supranuclear palsy in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof.
2. A method of treating the symptoms of progressive supranuclear palsy in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof is given prophylactically.
4. The method of claim 3 , wherein onset of progressive supranuclear palsy signs and symptoms are delayed.
5. The method of claim 1 , wherein the compound of formula (I), or a pharmaceutically acceptable salt thereof is given to the subject in need thereof within one week of diagnosis of progressive supranuclear palsy.
6. The method of claim 5 , wherein progression of progressive supranuclear palsy and symptoms thereof is impeded.
7. The method of claim 1 , wherein the compound of formula (I) is in the form of a besylate salt.
8. The method of claim 1 , wherein the therapeutically effective amount is from about 0.1 to about 15 milligrams.
9. The method of claim 8 , wherein the therapeutically effective amount is from about 1 to about 10 milligrams.
10. The method of claim 9 , wherein the therapeutically effective amount is from about 2 to about 6 milligrams.
11. The method of claim 10 , wherein the therapeutically effective amount is about 3 milligrams.
12. The method of claim 1 , wherein the pharmaceutical composition is administered to the subject daily.
13. The method of claim 2 , wherein the compound of formula (I) is in the form of a besylate salt.
14. The method of claim 2 , wherein the therapeutically effective amount is from about 0.1 to about 15 milligrams.
15. The method of claim 14 , wherein the therapeutically effective amount is from about 1 to about 10 milligrams.
16. The method of claim 15 , wherein the therapeutically effective amount is from about 2 to about 6 milligrams.
17. The method of claim 16 , wherein the therapeutically effective amount is about 3 milligrams.
18. The method of claim 2 , wherein the pharmaceutical composition is administered to the subject daily.
19. A method of treating progressive supranuclear palsy in a subject in need thereof comprising:
selecting a subject having an elevated level of neurofilament light chain protein in a sample from the subject compared to a reference level of neurofilament light chain protein;
wherein the sample comprises cerebrospinal fluid, blood, serum, or plasma; and
administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I),
or a pharmaceutically acceptable salt thereof.
20. The method of claim 19 , wherein the therapeutically effective amount is from about 1 to about 10 milligrams.